Study Evaluating Multiple Ascending Dose in Schizophrenia Patients

Phase 1TerminatedNCT00620568

Wyeth is now a wholly owned subsidiary of Pfizer32 enrolled

Overview

This is a randomized, inpatient, ascending multiple dose study to assess safety and tolerability of SLV-313 SR tablets administered orally to subjects with schizophrenia and schizoaffective disorder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Healthy

Interventions

SLV-313 SRDRUG

sustained release tablets taken once daily for 14 days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men, aged 18-50 years old * Women, aged 18-50 years old Exclusion Criteria: * Non-lactating women, aged 18-50 years old * Non-pregnant women, aged 18-50 years old

Outcomes

Primary Outcomes

Observe safety and tolerability

Time frame: 25 days

Secondary Outcomes

PK and PD profile

Time frame: 25 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.